The effect of HMGB1 and RAGE on the clinicopathological and prognostic features of prostate cancer

Abstract

As a DNA-binding protein, high mobility group box 1 (HMGB1) has been shown be involved in various biological activities, including transcription regulation, DNA repair, genomic stability, and extracellular signaling. Accumulating evidence indicates that HMGB1 has an important role in biological processes in cancer. Moreover, HMGB1 has been shown to have intracellular and extracellular roles, activating key cancerogenic signaling pathways. The main signal pathway is activated via the interaction of HMGB1 with its receptor, receptor for advanced glycation end-products (RAGE). In addition, overexpression of HMGB1/RAGE occurs in certain types of primary tumors and has been linked to increased metastasis and poorer prognosis. In our previous research, we demonstrated that co-expression of HMGB1 and RAGE is associated with cancer progression and poor patient outcome in prostate cancer (PCa). Together with the recent published evidence, we describe and speculate on the character of the HMGB1/RAGE axis in PCa progression and elaborate on future prospects for the application of potential strategies to target HMGB1 in PCa therapy.

Keywords

High mobility group box 1 / receptor for advanced glycation end-products / prostate cancer

References

[1] SungH,SiegelRL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] CenterMM,Lortet-TieulentJ.International variation in prostate cancer incidence and mortality rates.Eur Urol2012;61:1079-92

[3] BianchiME.Upwardly mobile proteins. Workshop: the role of HMG proteins in chromatin structure, gene expression and neoplasia.EMBO Rep2000;1:109-14 PMCID:PMC1084262

[4] CzuraCJ,TraceyKJ.Dual roles for HMGB1: DNA binding and cytokine.J Endotoxin Res2001;7:315-21

[5] EllermanJE,deVera M.Masquerader: high mobility group box-1 and cancer.Clin Cancer Res2007;13:2836-48

[6] StrosM.HMGB proteins: interactions with DNA and chromatin.Biochim Biophys Acta2010;1799:101-13

[7] LotzeMT.High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.Nat Rev Immunol2005;5:331-42

[8] UedaT.HMGB proteins and transcriptional regulation.Biochim Biophys Acta2010;1799:114-8

[9] AgrestiA,BianchiME.HMGB1 interacts differentially with members of the Rel family of transcription factors.Biochem Biophys Res Commun2003;302:421-6

[10] ŠtrosM,SaniSA.HMGB1-mediated DNA bending: Distinct roles in increasing p53 binding to DNA and the transactivation of p53-responsive gene promoters.Biochim Biophys Acta Gene Regul Mech2018;1861:200-10

[11] DasD.The binding interaction of HMG-1 with the TATA-binding protein/TATA complex.J Biol Chem2001;276:32597-605

[12] AmatoJ,BrancaccioD.Insights into telomeric G-quadruplex DNA recognition by HMGB1 protein.Nucleic Acids Res2019;47:9950-66 PMCID:PMC6765150

[13] ShenX.High-mobility group box 1 protein and its role in severe acute pancreatitis.World J Gastroenterol2015;21:1424-35 PMCID:PMC4316085

[14] BianchiME.HMG proteins: dynamic players in gene regulation and differentiation.Curr Opin Genet Dev2005;15:496-506

[15] SrinivasanM,PalmerA.HMGB1 in hormone-related cancer: a potential therapeutic target.Horm Cancer2014;5:127-39

[16] SimsGP,RietdijkST,CoyleAJ.HMGB1 and RAGE in inflammation and cancer.Annu Rev Immunol2010;28:367-88

[17] HeC,ZhangY,LiS.The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer.Oncoimmunology2021;10:1897295 PMCID:PMC7954423

[18] SharmaA,RajeswariMR.Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin.Cancer Invest2008;26:843-51

[19] YanHX,ZhangHL.p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release.J Hepatol2013;59:762-8 PMCID:PMC3805120

[20] MaedaS,ShibataW.Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer.Biochem Biophys Res Commun2007;360:394-400

[21] WangC,HuangH.Blocking the feedback loop between neuroendocrine differentiation and macrophages improves the therapeutic effects of enzalutamide (MDV3100) on prostate cancer.Clin Cancer Res2018;24:708-23

[22] RojasA,Perez-CastroR.HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism.Tumour Biol2016;37:3321-9

[23] NeeperM,BrettJ.Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.J Biol Chem1992;267:14998-5004

[24] Mercado-PimentelME,LiQ,JandovaJ.The S100P/RAGE signaling pathway regulates expression of microRNA-21 in colon cancer cells.FEBS Lett2015;589:2388-93 PMCID:PMC4582666

[25] KangR,ZhangQ.RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.Cell Death Dis2014;5:e1480 PMCID:PMC4237264

[26] KwakT,ErgonulA.Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.Oncogene2017;36:1559-72

[27] SasahiraT,BhawalUK.Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma.Histopathology2007;51:166-72

[28] ZillH,ErbersdoblerHF,FaistV.RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells.Biochem Biophys Res Commun2001;288:1108-11

[29] ElangovanI,ChenA.Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth.Biochem Biophys Res Commun2012;417:1133-8

[30] ZhouJ,GilvaryDL.HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells.Sci Rep2015;5:15085 PMCID:PMC4606829

[31] ZhaoCB,LuYJ,ZhouXH,ZhaoSC.Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.Am J Cancer Res2014;4:369-77 PMCID:PMC4106654

[32] LvDJ,HuangB.HMGB1 promotes prostate cancer development and metastasis by interacting with brahma-related gene 1 and activating the Akt signaling pathway.Theranostics2019;9:5166-82 PMCID:PMC6691575

[33] LinL,SunZ,DingG.Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.J Cancer Res Clin Oncol2012;138:11-22

[34] JiangW,LiX,DuanY.High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.Pathol Oncol Res2012;18:293-8

[35] YaoX,YangH,BieL.Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.J Cancer Res Clin Oncol2010;136:677-84

[36] IshiguroH,MiyoshiY,KubotaY.Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.Prostate2005;64:92-100

[37] KuniyasuH,KondoH,UkaiR.Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer.Oncol Rep2003;10:1863-8

[38] HeY,WangY,YangX.Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer.Cancer Res2013;73:629-39

[39] LiT,YuanT.Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.BJU Int2012;110:E1125-30

[40] HuangZ,ZhangL.Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway.Sci Rep2015;5:12807 PMCID:PMC4523846

[41] KishiS,HonokiK.Role of glycated high mobility group box-1 in gastric cancer.Int J Mol Sci2021;22:5185 PMCID:PMC8153607

[42] LiY,ZhongD,LiangH.High-mobility group box 1 protein activating nuclear factor-κB to upregulate vascular endothelial growth factor C is involved in lymphangiogenesis and lymphatic node metastasis in colon cancer.J Int Med Res2015;43:494-505

[43] DhumaleSS,PathakC.Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells.IUBMB Life2015;67:361-73

[44] SuZ,ZhuH.HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive feedback during nutrient depletion.Immunobiology2015;220:539-44

[45] ZhangQ,ParajuliKR.Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition.Oncogene2017;36:687-99 PMCID:PMC5213194

[46] ThapaD.Chronic inflammatory mediators enhance prostate cancer development and progression.Biochem Pharmacol2015;94:53-62

[47] SimonsBW,BrunoTC.A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression.J Pathol2015;235:478-89 PMCID:PMC4352321

[48] SciarraA,SalcicciaS.Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.J Inflamm (Lond)2016;13:35 PMCID:PMC5123292

[49] KangR,SchapiroNE.The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics.Oncogene2014;33:567-77 PMCID:PMC3795800

[50] TianJ,MaoSY.Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.Nat Immunol2007;8:487-96

[51] HuttunenHJ,Kuja-PanulaJ,RauvalaH.Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.Cancer Res2002;62:4805-11

[52] GnanasekarM,RamaswamyK.Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis.Int J Oncol2009;34:425-31

[53] BaoJM,LiuYW.AGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradation.Am J Cancer Res2015;5:1741-50 PMCID:PMC4497440

[54] ShettyAV,DakshinamoorthyG.18α-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes.Int J Oncol2011;39:635-40

[55] LiuJ,YangA,YangW.Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization.Am J Transl Res2016;8:4881-91 PMCID:PMC5126330

[56] PatekS,HengJ.Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients.Oncotarget2017;8:4875-87 PMCID:PMC5354877

[57] VerrijdtG,SchoenmakersE,ClaessensF.Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors.Biochem J2002;361:97-103 PMCID:PMC1222283

[58] BoonyaratanakornkitV,PrendergastP.High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells.Mol Cell Biol1998;18:4471-87 PMCID:PMC109033

[59] HenzlerC,YangR.Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.Nat Commun2016;7:13668 PMCID:PMC5141345

[60] ReebyeV,HabibNA.Intracellular adaptor molecules and AR signalling in the tumour microenvironment.Cell Signal2011;23:1017-21

[61] TsaoCF,LiuTT.Expression of high-mobility group box protein 1 in diabetic foot atherogenesis.Genet Mol Res2015;14:4521-31

[62] QiuYW,XuMY.Beneficial effects of dantrolene on sepsis-induced diaphragmatic dysfunction are associated with downregulation of high-mobility group box 1 and calpain-caspase-3 proteolytic pathway.J Surg Res2016;200:637-47

[63] XuK,LuSM.Autophagy induction contributes to the resistance to methotrexate treatment in rheumatoid arthritis fibroblast-like synovial cells through high mobility group box chromosomal protein 1.Arthritis Res Ther2015;17:374 PMCID:PMC4718027

[64] GnanasekarM,ZhengG.HMGB1: a promising therapeutic target for prostate cancer.Prostate Cancer2013;2013:157103 PMCID:PMC3666291

[65] WuX,YangH,ZhangQ.The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway.Mol Cell Biochem2013;380:249-57

[66] HeQ,LiXM,WangP.HMGB1 promotes the synthesis of pro-IL-1β and pro-IL-18 by activation of p38 MAPK and NF-κB through receptors for advanced glycation end-products in macrophages.Asian Pac J Cancer Prev2012;13:1365-70

[67] EriksonJM,MummidiS.Targeting TRAF3IP2 by genetic and interventional approaches inhibits ischemia/reperfusion-induced myocardial injury and adverse remodeling.J Biol Chem2017;292:2345-58 PMCID:PMC5313105

[68] vanHooren L,MoskalevI.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Eur J Immunol2017;47:385-93

[69] DengL,LiuSC.SDF-1 blockade enhances Anti-VEGF therapy of glioblastoma and can be monitored by MRI.Neoplasia2017;19:1-7 PMCID:PMC5149063

[70] WangX,LiH.The role of HMGB1 signaling pathway in the development and progression of hepatocellular carcinoma: a review.Int J Mol Sci2015;16:22527-40 PMCID:PMC4613322

[71] vanBeijnum JR,vander Linden E.Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature.Blood2006;108:2339-48

[72] KikuchiH,HasegawaH.Therapeutic potential of transgenic mesenchymal stem cells engineered to mediate anti-high mobility group box 1 activity: targeting of colon cancer.J Surg Res2014;190:134-43

[73] YangH,NapolitanoA.Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.Cell Death Dis2015;6:e1786 PMCID:PMC4669834

[74] SmolarczykR,MatuszczakS.The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy.Arch Immunol Ther Exp (Warsz)2012;60:391-9

[75] ChangHY,WuCH,YenGC.Glycyrrhizin attenuates the process of epithelial-to-mesenchymal transition by modulating HMGB1 initiated novel signaling pathway in prostate cancer cells.J Agric Food Chem2019;67:3323-32

[76] LiF,PanQ.The protective effect of PNU-282987, a selective α7 nicotinic acetylcholine receptor agonist, on the hepatic ischemia-reperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor κB activation in mice.Shock2013;39:197-203

[77] NakamuraY,IrieK.Recombinant human soluble thrombomodulin ameliorates cerebral ischemic injury through a high-mobility group box 1 inhibitory mechanism without hemorrhagic complications in mice.J Neurol Sci2016;362:278-82

[78] LiS,KumasakaK.Does enoxaparin interfere with HMGB1 signaling after TBI?.J Trauma Acute Care Surg2016;80:381-7; discussion 387-9 PMCID:PMC5345267

[79] HernandezC,PradereJP,FriedmanRA.HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis.J Clin Invest2018;128:2436-51 PMCID:PMC5983315

[80] CandolfiM,FouladD.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Clin Cancer Res2009;15:4401-14 PMCID:PMC2769255